Pharmaceuticals, Biotechnology and Life Sciences
— Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most…
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single…
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression…
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study…
Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active…
San Diego, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) — Sapu Nano today announced new biomarker data identifying a molecular signature…
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active…
Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of…
ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global,…
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology…